

Financial Highlights

		FY2010	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2014 (Jan-Mar) Standardizing the Company's business year <unaudited>	FY2015 1Q (Jan-Mar)	Estimate FY2015 (Jan-Jun)	Estimate FY2015 (Jan-Dec)
Net sales	(Billions of yen)	1,127.6	1,154.6	1,218.1	1,452.8	1,224.3	347.5	385.1	710.0	1,370.0
	YoY	4.0%	2.4%	5.5%	19.3%	7.9%		10.8%		
Operating income	(Billions of yen)	126.3	148.7	169.7	198.7	196.5	17.3	51.6	55.0	110.0
	YoY	28.2%	17.7%	14.1%	17.1%	7.4%		198.1%		
Ordinary income	(Billions of yen)	128.4	152.1	184.5	215.2	217.2	18.5	51.5	60.0	120.0
	YoY	17.7%	18.5%	21.3%	16.7%	8.9%		178.6%		
Net income	(Billions of yen)	82.4	92.2	122.4	151.0	143.1	12.0	34.0	40.0	80.0
	YoY	22.1%	11.9%	32.8%	23.3%	2.7%		183.4%		
R&D expenses	(Billions of yen)	164.7	159.2	192.4	249.0	172.9	77.0	44.7	115.0	230.0
	YoY	8.4%	-3.3%	20.8%	29.4%	4.6%		-41.9%		
Overseas net sales	(Billions of yen)	552.5	579.7	622.7	824.4	757.0	207.4	248.8	402.0	712.0
	% of net sales	49.0%	50.2%	51.1%	56.8%	61.8%		64.6%	56.6%	52.0%

(Yen)

Exchange rate (Yen)	FY2010	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2014 (Jan-Mar) Standardizing the Company's business year <unaudited>	FY2015 1Q (Jan-Mar)	FY2015
US\$	87.79	79.79	79.80	97.72	106.72	102.76	119.15	120.00
Euro	116.27	111.12	102.55	129.77	140.2	140.79	133.99	130.00

(Billions of yen)

Selling, general and administrative expenses	FY2010	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2014 (Jan-Mar) Standardizing the Company's business year <unaudited>	FY2015 1Q (Jan-Mar)	Estimate FY2015 (Jan-Jun)	Estimate FY2015 (Jan-Dec)
Selling, general and administrative expenses	622.3	616.6	654.6	812.4	681.5	225.5	223.9	440.0	820.0
(% of net sales)	55.2%	53.4%	53.7%	55.9%	55.7%	64.9%	58.2%	62.0%	59.9%
Promotion expenses	179.6	174.4	156.2	192.0	188.0	50.4	73.0		
Personnel expenses	97.9	99.8	103.7	124.0	97.9	34.6	37.0		
Advertising expenses	28.9	25.1	29.5	34.2	26.0	6.3	6.0		
R&D expenses	164.7	159.2	192.4	249.0	172.9	77.0	44.7	115.0	230.0
(% of net sales)	14.6%	13.8%	15.8%	17.1%	14.1%	22.2%	11.6%	16.2%	16.8%
R&D expenses of pharmaceutical business	153.4	149.3	183.5	240.8	166.1	74.3	42.3	110.0	220.0

(Billions of yen)

Capital expenditures	FY2010	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2014 (Jan-Mar) Standardizing the Company's business year <unaudited>	FY2015 1Q (Jan-Mar)	Estimate FY2015 (Jan-Jun)	Estimate FY2015 (Jan-Dec)
Capital expenditures	44.8	43.3	63.3	179.0	88.2	29.0	400.9	410.0	450.0

(Billions of yen)

Depreciation	FY2010	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2014 (Jan-Mar) Standardizing the Company's business year <unaudited>	FY2015 1Q (Jan-Mar)	Estimate FY2015 (Jan-Jun)	Estimate FY2015 (Jan-Dec)
Depreciation	48.1	48.1	45.5	49.8	45.5	14.2	18.3	34.0	72.0

From 1Q FY2011, the method of translating revenue and expense accounts of foreign subsidiaries was changed from the spot rate as of the reporting date to the average exchange rate. The method of presentation for upfront licensing payments received was changed from non-operating income to net sales. Figures for FY2010 have been adjusted retrospectively to apply the changes above.

Sales to Customers by Market

(Billions of yen)

Net sales by business segment	FY2010	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2014 (Jan-Mar) Standardizing the Company's business year <unaudited>	FY2015 1Q (Jan-Mar)	Change
Consolidated sales	1,127.6	1,154.6	1,218.1	1,452.8	1,224.3	347.5	385.1	10.8%
Pharmaceutical business	751.1	782.2	850.9	1,035.1	883.5	258.3	288.7	11.8%
Japan	319.9	326.5	351.8	372.9	273.7	88.0	85.0	-3.3%
North America	349.0	361.1	389.0	530.5	481.6	132.8	152.5	14.9%
Others	82.2	94.7	110.0	131.7	128.3	37.5	51.1	36.0%
Nutraceutical business	256.4	251.3	246.9	281.1	232.7	55.6	61.7	10.9%
Japan	154.1	147.4	142.3	147.5	109.8	26.2	25.6	-2.4%
North America	46.8	45.8	49.8	59.8	55.8	10.9	15.3	40.4%
Others	55.6	58.1	54.8	73.9	67.1	18.5	20.8	12.3%
Consumer products business	47.1	48.0	45.2	43.8	34.4	9.6	9.0	-5.3%
Japan	40.9	42.0	39.2	36.6	27.9	7.6	6.7	-11.9%
North America	5.5	5.4	5.4	6.9	6.1	1.9	2.3	17.7%
Others	0.7	0.6	0.6	0.3	0.3	0.1	0.1	76.4%
Other business	72.9	73.1	75.0	92.8	73.7	24.1	25.7	6.7%
Japan	60.1	59.1	62.0	71.4	55.9	18.3	18.9	3.2%
North America	1.4	1.3	1.4	2.3	1.8	0.6	0.4	-28.8%
Others	11.4	12.7	11.6	19.0	16.0	5.1	6.3	23.6%
Japan -total	575.1	574.9	595.3	628.3	467.3	140.1	136.3	-2.7%
North America - total	402.7	413.5	445.7	599.6	545.3	146.2	170.6	16.6%
Others - total	149.8	166.2	177.1	224.9	211.7	61.2	78.3	27.9%
Overseas net sales	552.5	579.7	622.7	824.4	757.1	207.4	248.8	19.9%
Overseas net sales ratio	49.0%	50.2%	51.1%	56.8%	61.8%	59.7%	64.6%	19.9%

From 1Q FY2011, the method of translating revenue and expense accounts of foreign subsidiaries was changed from the spot rate as of the reporting date to the average exchange rate. The method of presentation for upfront licensing payments received was changed from non-operating income to net sales. Figures for FY2010 have been adjusted retrospectively to apply the changes above.

Net Sales and Operating Income by Geographical and Business Segment

(1) Geographical segment

(Billions of yen)

	FY2010	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2014 (Jan-Mar) Standardizing the Company's business year <unaudited>	FY2015 1Q (Jan-Mar)	Change
Net sales	1,127.6	1,154.6	1,218.1	1,452.8	1,224.3	347.5	385.1	10.8%
Japan*	745.2	779.1	842.5	982.1	738.2	236.9	185.4	-21.7%
North America*	426.0	437.5	474.1	652.1	601.9	155.9	186.7	19.7%
Others*	132.5	142.4	138.2	204.4	189.6	56.7	64.5	13.9%
Eliminations/corporate	-176.2	-204.4	-236.7	-385.9	-305.4	-101.9	-51.5	

*Intersegment sales are included.

(Billions of yen)

	FY2010	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2014 (Jan-Mar) Standardizing the Company's business year <unaudited>	FY2015 1Q (Jan-Mar)	Change
Operating income	126.3	148.7	169.7	198.7	196.5	17.3	51.6	198.1%
Japan	106.3	142.5	160.8	217.5	156.2	31.9	22.6	-29.0%
North America	12.2	14.4	16.2	-5.0	12.8	-0.2	0.3	-
Others	6.8	3.7	6.4	1.9	16.8	0.0	10.4	-
Eliminations/corporate	1.0	-12.0	-13.8	-15.7	10.7	-14.4	18.2	

(2) Business segment

(Billions of yen)

	FY2010	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2014 (Jan-Mar) Standardizing the Company's business year <unaudited>	FY2015 1Q (Jan-Mar)	Change
Net sales	1,127.6	1,154.6	1,218.1	1,452.8	1,224.3	347.5	385.1	10.8%
Pharmaceutical business*	751.1	782.2	850.9	1,035.1	883.5	258.3	288.7	11.8%
Nutraceutical business*	258.7	254.8	251.8	287.1	238.2	57.0	63.6	11.5%
Consumer products business*	47.9	49.2	46.9	43.9	34.5	9.6	9.2	-4.6%
Other business*	106.9	108.6	111.7	130.3	102.2	32.4	34.1	5.2%
Eliminations/corporate	-37.0	-40.3	-43.1	-43.7	-34.2	-9.8	-10.4	

*Intersegment sales are included.

(Billions of yen)

	FY2010	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2014 (Jan-Mar) Standardizing the Company's business year <unaudited>	FY2015 1Q (Jan-Mar)	Change
Operating income	126.3	148.7	169.7	198.7	196.5	17.3	51.6	198.1%
Pharmaceutical business	142.8	168.5	187.9	212.8	204.8	29.6	60.6	104.8%
Nutraceutical business	18.4	22.1	21.4	25.4	21.9	-1.2	0.4	-
Consumer products business	-2.2	-2.3	-2.4	-2.2	-1.4	-0.4	-0.7	-
Other business	4.4	1.9	3.9	7.2	5.5	1.3	1.3	1.4%
Eliminations/corporate	-37.1	-41.6	-41.0	-44.5	-34.3	-12.0	-10.1	

From 1Q FY2011, the method of translating revenue and expense accounts of foreign subsidiaries was changed from the spot rate as of the reporting date to the average exchange rate. The method of presentation for upfront licensing payments received was changed from non-operating income to net sales. Figures for FY2010 have been adjusted retrospectively to apply the changes above.

【Pharmaceutical business】

(Billions of yen)

Product name	Company	FY2010	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2014 (Jan-Mar) Standardizing the Company's business year <unaudited>	FY2015 1Q (Jan-Mar)	Change	Estimate FY2015 (Jan-Jun)	Estimate FY2015 (Jan-Dec)
Antipsychotic agent <i>Abilify</i>	Otsuka Pharmaceutical	392.6	411.6	438.5	575.7	507.4	146.8	155.5	5.9%	223.0	282.0
North America		308.3	316.1	336.1	455.5	416.5	106.0	125.7	18.6%	164.0	180.0
<US\$ million>		<3,512>	<3,960>	<4,208>	<4,659>	<3,900>	<1,031>	<1,055>	2.4%	<1,365>	<1,500>
Japan		23.0	24.8	28.6	34.4	23.7	9.4	7.9	-16.2%	18.0	39.0
Others		61.2	70.7	73.9	85.8	67.2	31.4	21.8	-30.5%	41.0	63.0
Aripiprazole long acting injection <i>Abilify Maintena</i>	Otsuka Pharmaceutical				4.3	14.4	2.7	7.9	187.8%	15.5	40.0
Anti-platelet agent <i>Pletal/Pletal</i>	Otsuka Pharmaceutical	53.2	50.3	45.8	44.2	26.2	9.3	7.7	-16.6%	16.0	31.5
Japan		46.5	44.1	40.1	36.8	20.7	7.4	5.8	-21.8%	12.5	23.5
Others		6.7	6.2	5.7	7.4	5.5	1.9	2.0	3.7%	3.5	8.0
Anti-gastritis and anti-gastric ulcer agent <i>Mucosta</i>	Otsuka Pharmaceutical	30.7	28.7	23.0	22.0	12.9	4.9	4.1	-16.4%	8.0	15.5
Japan		27.8	26.0	20.5	18.8	10.1	4.0	2.9	-27.2%	6.0	11.5
Others		2.9	2.7	2.5	3.1	2.7	0.9	1.2	32.6%	2.0	4.0
Anti-metabolite <i>TS-1</i>	Taiho Pharmaceutical	37.1	36.5	37.0	37.4	24.0	6.7	6.8	1.5%	14.0	31.0
Anti-metabolite <i>UFT</i>	Taiho Pharmaceutical	15.7	12.9	11.2	9.5	6.3	1.9	1.7	-11.3%	3.5	7.0
Reduced folic acid formulation <i>Uzel</i>	Taiho Pharmaceutical	14.1	12.7	13.2	11.9	7.9	2.6	2.4	-8.1%	5.0	10.0
Anticancer <i>Lonsurf</i>	Taiho Pharmaceutical					2.3		0.6		3.0	9.0
Urinary incontinence / frequency treatment <i>P4 (Bup-4)</i>	Taiho Pharmaceutical	7.0	6.3	5.6	4.7	2.8	1.0	0.8	-22.5%	2.0	3.5
5-HT ₂ receptor antagonist <i>Aloxi</i>	Taiho Pharmaceutical	4.3	7.9	10.0	11.0	8.8	2.6	2.7	4.7%	5.5	11.5
Anticancer <i>Abraxane</i>	Taiho Pharmaceutical	1.1	3.2	3.7	8.8	8.2	2.2	3.6	62.2%	6.5	15.5
Antiepileptic <i>E Keppra</i>	Otsuka Pharmaceutical	0.8	4.8	10.5	15.8	13.2	4.3	4.4	2.3%	10.0	24.5
V ₂ receptor antagonist <i>Samsca</i>	Otsuka Pharmaceutical	3.2	6.7	12.8	21.0	20.8	5.7	8.4	48.8%	19.0	41.5
Mucin-production enhancing agent <i>Mucosta Ophthalmic Suspension</i>	Otsuka Pharmaceutical		0.1	1.0	2.9	2.8	0.9	1.1	23.9%	2.5	5.0
Parkinson's Disease, RLS* treatment <i>Neupro Patch</i>	Otsuka Pharmaceutical			0.2	2.6	4.7	0.9	1.6	80.3%	4.0	9.5
Anticancer <i>Sprycel</i> (collaboration with BMS)	Otsuka Pharmaceutical	8.0	7.6	12.0	26.1	22.9	6.1	6.7	10.2%	15.5	31.0
Antibiotic <i>Zosyn/Tazocin</i> (bulk supply)	Taiho Pharmaceutical	11.2	10.7	12.4	14.5	11.8	4.8	1.9	-59.9%	6.0	13.0
Diagnostics -total	Otsuka Pharmaceutical	6.6	7.9	8.8	12.6	8.5	5.1	4.0	-22.4%	7.5	13.5
Parenteral nutrition (clinical nutrition) -total		96.8	96.0	96.4	103.4	81.5	23.1	23.5	1.9%	51.0	107.0
Japan	Otsuka Pharmaceutical Factory	87.6	88.6	88.8	91.6	68.2	19.4	19.5	0.2%	42.0	87.5
Others		9.2	7.4	7.6	11.8	13.3	3.6	4.0	10.9%	9.0	19.5
Pharmaceutical business -total (excluding exports)	Japan	319.9	326.5	351.8	372.9	273.7	88.0	85.0	-3.3%	182.0	384.0
Pharmaceutical business -total	Total	751.1	782.2	850.9	1,035.1	883.5	258.3	288.7	11.8%	489.0	889.0
Milestone and upfront revenue		7.3	14.9	41.5	22.0	20.4	5.2	11.6	121.7%	13.0	63.5

From 1Q FY2011, the method of translating revenue and expense accounts of foreign subsidiaries was changed from the spot rate as of the reporting date to the average exchange rate. The method of presentation for upfront licensing payments received was changed from non-operating income to net sales. Figures for FY2010 have been adjusted retrospectively to apply the changes above.

* RLS: Restless Legs Syndrome

【Neutraceuticals business】

(10 thousand cases)

Product name	Company	FY2010	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2014 (Jan-Mar) Standardizing the Company's business year	FY2015 1Q (Jan-Mar)	Change
<i>Pocari Sweat</i> 1 case: 24 bottles, and other (10 thousand cases)	Otsuka Pharmaceutical								
Japan		3,234	2,912	2,709	2,860	2,006	430	446	3.9%
Overseas		1,597	1,963	2,151	2,684	2,256	497	454	-8.5%
<i>SOYJOY</i> 1 case: 48 bars (10 thousand cases)	Otsuka Pharmaceutical								
Japan		113	100	88	109	107	19	24	26.2%
Overseas		28	20	12	16	12	4	5	12.9%
<i>Oronamin C</i> 1 case: 50 bottles (10 thousand cases)	Otsuka Pharmaceutical	1,051	1,081	1,067	1,105	830	207	193	-6.8%
<i>Calorie Mate</i> 1 case: 4 bars×30, and other (10 thousand cases)	Otsuka Pharmaceutical	392	351	335	340	280	78	78	-0.1%
<i>Tiovita Drink</i> 1 case: 50 bottles (10 thousand cases)	Taiho Pharmaceutical	484	532	489	402	290	76	64	-16.3%
<i>Solmack</i> (10 thousand of bottles)	Taiho Pharmaceutical	1,571	1,579	1,588	1,479	1,174	251	271	7.9%

* Overseas sales include sales of consolidated subsidiaries only.

【Consumer products business】

(10 thousand cases)

Product name	Company	FY2010	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2014 (Jan-Mar) Standardizing the Company's business year	FY2015 1Q (Jan-Mar)	Change
<i>Bottled Water</i> 1 case: 24 bottles (10 thousand cases)	Otsuka Foods	674	679	567	580	396	105	78	-26.2%
<i>Match</i> 1 case: 24 bottles (10 thousand cases)	Otsuka Foods	371	451	521	514	447	96	91	-6.0%
<i>Other (tea drinks and other)</i> 1 case: 24 bottles (10 thousand cases)	Otsuka Foods	267	317	300	265	177	54	47	-13.1%

【Other business】

(Billions of yen)

Product name	Company	FY2010	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2014 (Jan-Mar) Standardizing the Company's business year <unaudited>	FY2015 1Q (Jan-Mar)	Change
Functional chemicals	Otsuka Chemical	26.3	27.9	26.6	33.5	26.6	8.9	8.8	-0.7%
Fine chemicals	Otsuka Chemical	12.4	9.3	10.2	10.1	7.3	3.1	2.9	-4.3%

Otsuka Group - Pipeline Information

(as of Mar 31, 2015)

Code / <Brand name>	Generic name	Origin	Category	Indication / Dosage form	Country / Region	Development status
Central nervous system, neurological disorders						
OPC-14597 <Abilify*>	aripiprazole	Otsuka Pharmaceutical	Dopamine partial agonist	Schizophrenia / Depot injection	JP	Approved
<Abilify Maintena*>: Depot injection				Autism / Oral	JP	Phase III
				Bipolar I / Depot injection	JP, US, EU	Phase III
				Agitation associated with dementia of the Alzheimer's type / Oral	JP	Phase III
L059 <E Keppra>	levetiracetam	UCB	Anti-epileptic drug	Epilepsy (generalized onset seizures) / Oral, Injection	JP	Filed
				Epilepsy (partial onset seizures/mono therapy) / Oral, Injection	JP	Approved
OPC-34712	brexpiprazole	Otsuka Pharmaceutical	Dopamine partial agonist	Adjunctive therapy for major depressive disorder / Oral	US EU	Filed Phase III
				Schizophrenia / Oral	US JP, EU	Filed Phase III
				ADHD (Adults) / Oral	US	Phase II
				Agitation associated with dementia of the Alzheimer's type / Oral	US, EU	Phase III
				Posttraumatic stress disorder (PTSD) / Oral	US, EU	Phase III
Lu AE58054	idalopirdine	Lundbeck	selective 5-HT ₆ receptor antagonist	Alzheimer's disease / Oral	US, EU	Phase III
ASC-01	aripiprazole, sertraline	Otsuka Pharmaceutical	Dopamine partial agonist/ Selective serotonin reuptake inhibitor	Major depressive disorder / Oral	JP, Asia	Phase III
AVP-923	dextromethorphan, quinidine	Avanir	NMDA receptor inhibitor / Sigma 1 receptor agonist	Agitation associated with dementia of the Alzheimer's type / Oral	US	Phase II
				Dyskinesia associated with Parkinson's disease / Oral	US	Phase II
AVP-786	deuterium-modified dextromethorphan, quinidine	Avanir	NMDA receptor inhibitor / Sigma 1 receptor agonist	Adjunctive therapy for major depressive disorder / Oral	US	Phase II
AVP-825	sumatriptan	Avanir	5-HT _{1B/1D} receptor agonist	Acute migraine / Nasal powder	US	Filed
TAS-205		Taiho Pharmaceutical	PGD synthase-inhibitor	Duchenne Muscular Dystrophy (DMD) / Oral	JP	Phase I
Lu AA36143	nalmefene	Lundbeck	Opioid receptor antagonist	Lowing alcohol consumption of alcohol dependence/ Oral	JP	Phase III

Note: In general, Otsuka disclose compounds that are in Phase II or later stage of development, although some compounds in Phase I are disclosed in the above table.

*: Product names used outside Japan.

(as of Mar 31, 2015)

Code / <Brand name>	Generic name	Origin	Category	Indication / Dosage form	Country / Region	Development status
Oncology						
S-1 <TS-1> Japan, Korea <Teysuno*> EU	tegafur, gimeracil, oteracil	Taiho Pharmaceutical	Anti-cancer (Anti-metabolite)	Uterocervical cancer / Oral	JP, Asia	Phase III
TAS-102 <Lonsurf>	trifluridine, tipiracil	Taiho Pharmaceutical	Anti-cancer	Colorectal cancer / Oral	US·EU Asia	Filed Phase III
TAS-118	tegafur, gimeracil, oteracil, folinate	Taiho Pharmaceutical	Anti-cancer (Anti-metabolite)	Pancreatic cancer / Oral	JP, Asia	Phase III
				Gastric cancer / Oral	JP, Asia	Phase III
<Sativex*>	nabiximols	GW Pharmaceuticals	Cannabinoid (THC, CBD)	Cancer pain / Oral spray	US	Phase III
OCV-101		OncoTherapy Science	Therapeutic cancer vaccine	Pancreatic cancer / Injection	JP	Phase II
<Spricel>	dasatinib	BMS	Anti-cancer (Molecular-targeted drug)	Pancreatic cancer / Oral	US, EU	Phase II
SGI-110		Astex	Anti-cancer	Ovarian cancer / Injection	US, EU	Phase II
				Hepatocellular carcinoma / Injection	US, EU	Phase II
				Acute Myeloid Leukemia, Myelodysplastic syndrome / Injection	US	Phase II
				Acute Myeloid Leukemia / Injection	US, EU	Phase III
				Acute Myeloid Leukemia / Injection	JP	Phase I
AT13387		Astex	Anti-cancer (Molecular-targeted drug)	Prostate cancer / Injection	US, EU	Phase II
				NSCLC / Injection	US, EU	Phase II
AT7519		Astex	Anti-cancer (Molecular-targeted drug)	Multiple myeloma / Injection	US	Phase II
ASTX727		Astex	Anti-cancer	Myelodysplastic syndrome / Oral	US	Phase I
ET-743	trabectedin	PharmaMar	Anti-cancer	Malignant soft tissue sarcoma / Injection	JP	Filed
OPB-31121		Otsuka Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Anti-cancer / Oral	JP, Asia	Phase I
OPB-51602		Otsuka Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Anti-cancer / Oral	JP, US, Asia	Phase I
OPB-111077		Otsuka Pharmaceutical	Anti-cancer	Solid tumors / Oral	US, Asia	Phase I
OPB-111001		Otsuka Pharmaceutical	Anti-cancer	Solid tumors / Oral	EU	Phase I
TAS-114		Taiho Pharmaceutical	Anti-cancer (Antitumor enhancer)	Solid tumors / Oral	JP, US, EU	Phase I
TAS-115		Taiho Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Solid tumors / Oral	JP	Phase I
TAS-116		Taiho Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Solid tumors / Oral	JP	Phase I
TAS-117		Taiho Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Solid tumors / Oral	JP	Phase I
TAS-119		Taiho Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Solid tumors / Oral	US, EU	Phase I
TAS-120		Taiho Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Solid tumors / Oral	JP, US, EU	Phase I
TAS-121		Taiho Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Solid tumors / Oral	JP	Phase I
OCV-501		Otsuka Pharmaceutical	WT1 targeted cancer vaccine	Secondary Prevention of elderly acute myeloid leukemia / Injection	JP, Asia	Phase II
OCV-C02		OncoTherapy Science	Therapeutic cancer vaccine	Colorectal Cancer / Injection	JP	Phase I
OPC-12759	rebamipide	Otsuka Pharmaceutical	Oral mucosal protectant / mucosal healing agent	Stomatitis associated with cancer chemoradiotherapy / Solution	JP	Phase II

Note: In general, Otsuka disclose compounds that are in Phase II or later stage of development, although some compounds in Phase I are disclosed in the above table.
*: Product names used outside Japan.

Otsuka Group - Pipeline Information

(as of Mar 31, 2015)

Code / <Brand name>	Generic name	Origin	Category	Indication / Dosage form	Country / Region	Development status
Cardiovascular						
OPC-41061 <Samsca*>	tolvaptan	Otsuka Pharmaceutical	V ₂ receptor antagonist	Hepatic edema / Oral	Asia	Filed
				Autosomal dominant polycystic kidney disease / Oral	EU US	Filed Phase III
				Cardiac edema / Oral	Asia	Filed
				Carcinomatous edema / Oral	JP	Phase II
				Volume overload in hemodialysis / Oral	JP	Phase II
				Volume overload in peritoneal dialysis / Oral	JP	Phase II
OPC-108459		Otsuka Pharmaceutical		Paroxysmal and persistent atrial fibrillation / Injection	JP, US	Phase I
Other areas						
YP-18 <Zosyn*>	tazobactam, piperacillin	Taiho Pharmaceutical	Antibiotic agent	Febrile neutropenia / Injection	JP	Filed
TAC-202	bilastine	Faes Farma	H ₁ receptor antagonist	Allergic rhinitis / Oral	JP	Phase III
				Chronic urticaria, Pruritus associated with skin disease / Oral	JP	Phase II / III
OPC-67683 <Delyba*>	delamanid	Otsuka Pharmaceutical	Anti-tuberculosis agent	Multidrug-resistant tuberculosis / Oral	US	Phase III
				Multidrug-resistant tuberculosis for pediatrics / Oral	EU	Phase II
OPC-12759E <Mucosta Ophthalmic Suspension>	rebamipide	Otsuka Pharmaceutical	Mucin-production enhancing agent	Dry eyes / Eye drops MD (Multi Dose)	JP	Phase III
OPB-2045G	olanexidin	Otsuka Pharmaceutical Factory	Anti-septics	Patient preoperative preparation / Topical	JP	Filed
OPF-105	Amino Acid, Carbohydrate, and Fat Emulsion Injection with Electrolytes and Vitamins	Otsuka Pharmaceutical Factory	Protein and amino acid preparation	Peripheral parenteral nutrition solution / Injection	JP	Phase III
OPF-108	Amino Acid and Carbohydrate, and with Electrolytes and Vitamins	Otsuka Pharmaceutical Factory	Protein and amino acid preparation	Total parenteral nutrition / Injection	JP	Phase III
OPC-6535	tetomilast	Otsuka Pharmaceutical	Anti-inflammatory agent	COPD / Oral	JP, US, Asia	Phase II
ACU-4429	emixustat	Acucela	Visual cycle modulator	Dry AMD / Oral	US	Phase II b / III
OPA-6566		Otsuka Pharmaceutical	A _{2a} receptor agonist	Glaucoma / Eye Drops	US	Phase I / II
OPC-1085EL	carteolol, latanoprost	Otsuka Pharmaceutical	β receptor antagonist / PGF _{2α} analogue	Glaucoma / Eye Drops	JP	Phase III
OPA-15406		Otsuka Pharmaceutical	PDE4 inhibitor	Atopic Dermatitis / Ointment	US	Phase II
Diagnostics						
C13-URA	Uracil (2-13C)	Otsuka Pharmaceutical	13C-uracil breath test	For the diagnosis of gastric emptying disorders / In-vivo diagnostic drug	US	Phase II
C13-CAC	Calcium (13C)	Otsuka Pharmaceutical	13C-Calcium Carbonate breath test	For measurement of gastric acidity / In-vivo diagnostic agent	JP	Phase II

Note: In general, Otsuka disclose compounds that are in Phase II or later stage of development, although some compounds in Phase I are disclosed in the above table.

*: Product names used outside Japan.

Changes in Pipeline information Since December 2014

Code / <Brand name>	Generic name	Origin	Category	Indication / Dosage form	Country / Region	Development status	Change from 2014 4Q
Central nervous system, neurological disorders							
<Abilify Maintena*>: <Depot injection>	aripiprazole	Otsuka Pharmaceutical	Dopamine partial agonist	Schizophrenia / Depot injection	JP	Approved	Filed→Approval
L059 <E Keppra>	levetiracetam	UCB	Anti-epileptic drug	Epilepsy (generalized onset seizures) / Oral, Injection	JP	Filed	Phase III→Filed
				Epilepsy (partial onset seizures/mono therapy) / Oral, Injection	JP	Approved	Filed→Approval
Lu AA36143	nalmefene	Lundbeck	Opioid receptor antagonist	Lowering alcohol consumption of alcohol dependence/ Oral	JP	Phase III	Newly added
Oncology							
TAS-102 <Lonsurf>	trifluridine, tipiracil	Taiho Pharmaceutical	Anti-cancer	Colorectal cancer / Oral	EU	Filed	Phase III→Filed
TAS-118	tegafur, gimeracil, oteracil, folinate	Taiho Pharmaceutical	Anti-cancer (Anti-metabolite)	Gastric cancer / Oral	JP, Asia	Phase III	Newly added
SGI-110	guadecitabine	Astex	Anti-cancer	Acute myeloid leukemia / Injection	US, EU	Phase III	Newly added
				Acute myeloid leukemia / Injection	JP	Phase I	Newly added
ET-743	trabectedin	PharmaMar	Anti-cancer	Malignant soft tissue sarcoma / Injection	JP	Filed	Phase II→Filed
TAS-117		Taiho Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Solid tumors / Oral	JP	Phase I	Newly added